Literature DB >> 9862446

Identification of a retinoic acid responsive aldoketoreductase expressed in HL60 leukaemic cells.

K I Mills1, A F Gilkes, M Sweeney, M A Choudhry, L J Woodgate, C M Bunce, G Brown, A K Burnett.   

Abstract

Neutrophil and monocyte differentiation can be induced in HL60 leukaemia cells by all-trans-retinoic acid (ATRA) and 1alpha,25-dihydroxyvitamin D3 (D3), respectively, whose differentiating effects can be enhanced by exposure to 'anti-inflammatory agents' and steroids. We have provided evidence that this potentiation is via inhibition of the activity of an enzyme of the aldoketoreductase (AKR) family, but had failed to identify expression of known AKRs in HL60 cells. In this study, we have identified a previously unclassified aldoketoreductase family member (termed HAKR e) that is expressed in HL60 cells. HAKR e is dramatically and transiently up-regulated in HL60 cells within 24 h of exposure to ATRA, further supporting the proposition that a member(s) of this family of enzymes play(s) a role in controlling cell growth and/or differentiation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9862446     DOI: 10.1016/s0014-5793(98)01435-5

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  6 in total

1.  Isocitrate dehydrogenase 2 inhibitor enasidenib synergizes daunorubicin cytotoxicity by targeting aldo-keto reductase 1C3 and ATP-binding cassette transporters.

Authors:  Anselm Morell; Youssif Budagaga; Dimitrios Vagiannis; Yu Zhang; Lenka Laštovičková; Eva Novotná; Andrew Haddad; Melodie Haddad; Ramon Portillo; Jakub Hofman; Vladimír Wsól
Journal:  Arch Toxicol       Date:  2022-08-16       Impact factor: 6.168

2.  Selective AKR1C3 Inhibitors Potentiate Chemotherapeutic Activity in Multiple Acute Myeloid Leukemia (AML) Cell Lines.

Authors:  Kshitij Verma; Tianzhu Zang; Nehal Gupta; Trevor M Penning; Paul C Trippier
Journal:  ACS Med Chem Lett       Date:  2016-06-22       Impact factor: 4.345

3.  Combined bezafibrate and medroxyprogesterone acetate: potential novel therapy for acute myeloid leukaemia.

Authors:  Farhat L Khanim; Rachel E Hayden; Jane Birtwistle; Alessia Lodi; Stefano Tiziani; Nicholas J Davies; Jon P Ride; Mark R Viant; Ulrich L Gunther; Joanne C Mountford; Heinrich Schrewe; Richard M Green; Jim A Murray; Mark T Drayson; Chris M Bunce
Journal:  PLoS One       Date:  2009-12-07       Impact factor: 3.240

4.  Potent and Highly Selective Aldo-Keto Reductase 1C3 (AKR1C3) Inhibitors Act as Chemotherapeutic Potentiators in Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.

Authors:  Kshitij Verma; Tianzhu Zang; Trevor M Penning; Paul C Trippier
Journal:  J Med Chem       Date:  2019-03-25       Impact factor: 7.446

5.  Lack of functional and expression homology between human and mouse aldo-keto reductase 1C enzymes: implications for modelling human cancers.

Authors:  Pedro Veliça; Nicholas J Davies; Pedro P Rocha; Heinrich Schrewe; Jonathan P Ride; Chris M Bunce
Journal:  Mol Cancer       Date:  2009-12-14       Impact factor: 27.401

6.  Retinoid differentiation therapy for common types of acute myeloid leukemia.

Authors:  Geoffrey Brown; Philip Hughes
Journal:  Leuk Res Treatment       Date:  2012-06-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.